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http://dx.doi.org/10.1016/j.ccr.2014.07.014SUMMARYWe describe the landscape of somatic genomic alterations of 66 chromophobe renal cell carcinomas
(ChRCCs) on the basis of multidimensional and comprehensive characterization, including mtDNA and
whole-genome sequencing. The result is consistent that ChRCCoriginates from the distal nephron compared
with other kidney cancers with more proximal origins. Combined mtDNA and gene expression analysis
implicates changes in mitochondrial function as a component of the disease biology, while suggestingCancer Cell 26, 319–330, September 8, 2014 ª2014 Elsevier Inc. 319
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Comprehensive Genomic Analysis of ChRCCalternative roles for mtDNA mutations in cancers relying on oxidative phosphorylation. Genomic rearrange-
ments lead to recurrent structural breakpoints within TERT promoter region, which correlates with highly
elevated TERT expression and manifestation of kataegis, representing a mechanism of TERT upregulation
in cancer distinct from previously observed amplifications and point mutations.INTRODUCTION
Rare tumor types offer a unique opportunity to investigate and
discover mechanisms of tumorigenesis. Chromophobe renal
cell carcinoma (ChRCC) is a subtype of renal cell carcinoma
(RCC), representing 5% of this heterogeneous group of can-
cers arising from the nephron (Sto¨rkel et al., 1997), with 3,000
new cases annually in the United States (Jemal et al., 2013).
Although ChRCC typically exhibits an indolent pattern of local
growth, with greater than 90% 10-year cancer-specific survival
(Amin et al., 2002; Przybycin et al., 2011), aggressive features
and metastasis can occur. ChRCC is associated with a distinct
aneuploidy pattern (Speicher et al., 1994); however, genome-
wide evaluation of its somatic mutation spectrum has not
been reported. ChRCC is associated with germline mutation
of FLCN in the autosomal-dominant cancer predisposition
Birt-Hogg-Dube´ (BHD) syndrome, in which 34% of BHD-
associated kidney tumors are ChRCC (Nickerson et al., 2002;
Pavlovich et al., 2002; Schmidt et al., 2001), and with germline
mutation of PTEN in Cowden syndrome (Shuch et al., 2013).
Previous studies have suggested a nonglycolytic metabolic
profile for ChRCC, using 18F-fluorodeoxyglucose positron
emission tomography/computed tomography (Ho et al.,
2012), and have shown that the genomic profile comprises
unique whole-chromosome losses rather than focal events
(Speicher et al., 1994).
Genomic profiling of rare cancers, such as ChRCC, can
provide a more complete picture of the disease. Although very
large sample numbers (>5,000) may be needed for some disease
types in order to detect rare mutational events (Lawrence et al.,
2014), in many cases, there remain undiscovered frequent
mutations that drive disease. When data integration across
multiple platforms is applied, patterns observed in one data
type may be reflected in the other data types, building a more
conclusive set of findings with regard to revealing driver events.
For example, early DNA microarray studies of breast cancer, for
example, globally assaying a single data type for 65 tumors
(Perou et al., 2000) and incorporating clinical data, have had an
enduring impact on our understanding of breast and other
cancers, while PBRM1 mutations were discovered in clear cell
kidney cancers from an initial analysis of just 25 tumors (VarelaSignificance
Rare diseases can provide insights into the biology of more c
deconstructed ChRCC, a tumor characterized by slow but pe
therapies. Global molecular patterns provide clues as to this ca
component of the molecular portrait of ChRCC. The observed
instability in precancerous cells undergoing the crisis stage
data will facilitate further discovery of driver alterations extend
eses that can advance our molecular understanding of this an
320 Cancer Cell 26, 319–330, September 8, 2014 ª2014 Elsevier Incet al., 2011). Understudied cancers, such as ChRCC, may hold
this potential for discovery as well.
RESULTS
Copy-Number and Whole-Exome Analysis
The Cancer Genome Atlas (TCGA) collected a total of 66 pri-
mary ChRCC specimens (Table S1 available online) with
matching normal tissue/blood, in order to better characterize
the molecular basis of this cancer using multiple data platforms
(Table 1; Table S1). Our comprehensive analysis of ChRCC
involved a systematic examination by data type, including
copy number and whole-exome sequencing (WES). By SNP
array analysis, loss of one copy of the entire chromosome,
for most or all of chromosomes 1, 2, 6, 10, 13, and 17, was
seen in the majority of cases (86%; Figure 1A). Losses of
chromosomes 3, 5, 8, 9, 11, 18, and 21 were also noted at
significant frequencies (12%–58%). There were no focal
copy-number events by GISTIC analysis (Mermel et al., 2011),
suggestive of a simpler chromosomal landscape for ChRCC
in comparison with that of other cancers, including the more
common clear cell type RCC (ccRCC). We subdivided our
ChRCC cases according to previously defined histologic cate-
gories of ‘‘classic’’ (n = 47), which demonstrate the classical
pale cytoplasmic features for which the disease was named,
and ‘‘eosinophilic’’ (n = 19), based on abundant, eosinophilic
cytoplasm and densely packed mitochondria, by expert
consensus pathology review (Brunelli et al., 2005). Although
all classic cases showed the characteristic ChRCC copy-num-
ber pattern, only about half of the eosinophilic cases (10 of 19)
showed the same, with four eosinophilic cases showing no
copy-number alterations. This suggests a degree of genomic
heterogeneity that distinguishes the histopathology-based
classifications.
WES of 66 ChRCC cases targeted186,260 exons in18,091
genes, achieving 90% target coverage at a minimum of 203
for both tumor and matched normal samples. Overall, ChRCC
displayed a low median rate of exonic somatic mutations
(0.4 per Mb) compared with most tumors (Alexandrov et al.,
2013), approximately 3-fold less than the median number
seen in ccRCC (which differences were also observable withinommon pathologies. Using diverse molecular platforms, we
rsistent growth and high resistance to conventional cancer
ncer’s cell of origin. mtDNA alterations represent an integral
TERT promoter rearrangements may result from genomic
of immortalization, leading to activated telomerase. These
ing beyond the exome as well as the generation of hypoth-
d other cancers.
.
Table 1. Summary of Data Types
Data Type Platforms Cases Data Access
TCGA core sample set (n = 66 total cases)
Whole-exome
DNA sequence
Illumina 66 controlled
Whole-genome
DNA sequence
Illumina 50 controlled
mtDNA sequence Illumina
(LR-PCRa)
61 controlled
DNA copy
number/genotype
Affymetrix
SNP 6
66 controlled: CEL files
open: copy number
mRNA expression Illumina 66 controlled: BAM files
open: expression
miRNA expression Illumina 66 controlled: BAM files
open: expression
CpG DNA
methylation
Illumina
450,000 array
66 open
See also Table S1.
aTo amplify mitochondrial DNA.
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Figure 1. Gene Mutations and Copy Alterations in ChRCC
(A) Copy-number alterations (red, gain; blue, loss of one copy) by cytoband
region (marker: darker color, p arm; lighter color, q arm) in ChRCC and ccRCC.
(B) Genomic alterations in ChRCC samples, each column representing a
sample.
See also Figure S1 and Table S2.
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Comprehensive Genomic Analysis of ChRCCstrata defined by age or stage), with the one exception showing
elevated somatic mutation rate (>10/Mb by WES) and mutation
signature of DNA mismatch repair deficiency (Alexandrov
et al., 2013). Using alternative sequencing instrumentation, we
validated 60 somatic mutation events for a set of 30 genes
both arising fromWES and having inferred biologically relevance
(Table S2). Although our lower case numbers limited purely
data-driven approaches to assigning statistical significance to
infrequently mutated genes, we did have sufficient power to
identify significant genes with a frequency of 10% (Lawrence
et al., 2014). Only two significant genes were thus identified
(MutSig q < 0.1): TP53 and PTEN.
TP53 was frequently mutated in 32% of cases (21 of the 66
profiled), with mutations correlating with decreased expression
of p53 transcriptional targets (Figures S1A–S1C). PTEN was
the next most frequently mutated, with 9% (6 of 66) nonsilent
mutations detected. No other genes were found to be mutated
at a frequency higher than 5%, though mutations involving
cancer-relevant genes were found at lower frequencies (Fig-
ure 1B). Mutations were seen in MTOR (2 cases), NRAS (1 acti-
vating mutation), and TSC1 or TSC2 (4 cases), and two homo-
zygous deletions were seen in PTEN, indicating that genomic
targeting of the mTOR pathway occurred overall in 15 (23%)
of 66 ChRCCs (Figure 1B). Biological significance could be
ascribed to infrequently mutated genes, in terms of associated
pathways, including the p53 and PTEN pathways (Table S2).
The genetic diseases BHD and tuberous sclerosis complex
both predispose to the development of ChRCC, and associated
mutations converge in activation of the PTEN signaling path-
way. Our study focused on sporadic disease, and a surprisingly
high percentage (47%) of our core cases did not show alter-
ations associated with either PTEN or p53 pathways. Because
no additional pathways involving sizable numbers of cases
could be implicated from the exome data, our search was
extended to mtDNA and structural variant (SV) analysis, as
described below.CaDNA Methylation and RNA Analysis
TCGA data platforms allow for comparisons between tumor
types (Cancer Genome Atlas Research Network et al., 2013).
For example, we observed widespread differences in DNA
methylation between ChRCC and ccRCC (Figure 2A), involving
over 64,000 loci out of 450,000 profiled (p < 0.001, t test using
logit-transformed data, beta value difference > 0.1). ChRCC
displayed more hypomethylation and fewer hypermethylation
events compared with ccRCC. We also observed epigenetic
silencing of CDKN2A/p16 in four ChRCC cases (Figure 2B). In
principle, differential DNA methylation patterns could involvencer Cell 26, 319–330, September 8, 2014 ª2014 Elsevier Inc. 321
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B
D
Figure 2. DNA Methylation and Gene Expression Differences between ChRCC and ccRCC
(A) Heatmap showing a randomly selected 20% of a total of 64,021 DNA methylation loci in normal kidney, ChRCC, and ccRCC (red, high; blue, low).
(B) Epigenetic silencing of CDKN2A locus in four ChRCC cases. Exon 1a expression corresponds to p16INK4a isoform.
(C) A cartoon of nephron (left) and heatmaps showing intersample correlations (red, positive) between profiles of kidney tumors (columns; TCGA data, arranged
by subtype) and profiles of kidney nephron sites (rows; data set from Cheval et al., 2012). CCD, kidney cortical collecting duct; CNT, kidney connecting tubule;
CTAL, kidney cortical thick ascending limb of Henle’s loop; DCT, kidney distal convoluted tubule; Glom, kidney glomerulus; MTAL, kidney medullary thick
ascending limb of Henle’s loop; OMCD, kidney outer medullary collecting duct; S1/S3, kidney proximal tubule.
(D) Genes showing coordinate methylation and expression changes between ChRCC and ccRCC, with the corresponding patterns in the nephron by anatomical
site.
See also Figure S2 and Tables S3, S4, and S5.
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Comprehensive Genomic Analysis of ChRCCcancer-relevant pathways but may also reflect the cell of origin
of the cancer (Shen and Laird, 2013). On the basis of immuno-
histochemical analyses (Prasad et al., 2007), ChRCC has been
postulated to arise from intercalated cells in the distal convoluted
tubule of the nephron, while ccRCC is thought to arise from cells
in the proximal convoluted tubule; however, this issue has
remained unresolved. The above DNA methylation patterns
were consistent with distinct origins, leading us to further explore
these origins using gene expression data.
We examined our gene expression data in the context of
an external gene expression data set of normal tissue microdis-
sected from various regions of the nephron (Cheval et al., 2012).
Supervised analysis, globally comparing each TCGA ChRCC or
ccRCC tumor expression profile (n = 66 and n = 417, respec-
tively) with that of each sample in the nephron atlas, showed
high mRNA expression correlations for ChRCC with distal re-
gions of the nephron. ccRCC gene expression, however, was
correlated with patterns associated with the proximal nephron
(Figure 2C). These associations were also evident when focusing322 Cancer Cell 26, 319–330, September 8, 2014 ª2014 Elsevier Incon the subset of differential genes in ChRCC versus ccRCC
associated with inverse DNA methylation changes (Figure 2D).
These results put into context many of the widespreadmolecular
differences between these two kidney cancer types, as well as
suggesting that cancers may be defined in part by cell of origin
in addition to genetic aberrations.
In addition to widespread differences in gene expression be-
tween ChRCC and ccRCC, and differences from normal kidney
(Figure S2A and Table S3), unsupervised clustering of mRNA
profiles indicated further molecular heterogeneity within ChRCC,
with at least two subsets identified (Figure S2B) as defined by
differential gene expression patterns. Cluster analysis of micro-
RNA (miRNA) profiles also indicated heterogeneity (Figure S2C),
and we could identify anticorrelations between miRNAs and
their predicted mRNA targets (Table S4), including an anti-
correlation (false discovery rate [FDR] < 0.01) involving miR-
145 (low in ChRCC versus normal) and the complex I-associated
NDUFA4 gene (Figure S2D) (Kano et al., 2010). Molecular corre-
lates of patient survival in ChRCC were identifiable at levels of.
A B Figure 3. Molecular Alterations in ChRCC
Involve Mitochondria
(A) Mutations and gene expression differences
between ChRCC and normal kidney in the context
of the mitochondrion. Red and blue shading rep-
resents increased and decreased expression of
nuclear-encoded genes, respectively, in ChRCC;
two-sided t test and fold change by unpaired
analysis. Mutation rates are also indicated for
mtDNA-encoded genes (not evaluated for ex-
pression): gray, no mutation; yellow, mutations
detected.
(B) mtDNA copy-number analysis; p value by
two-sided t test with unequal variance. Box plots
represent 5%, 25%, median, 75%, and 95%.
See also Figure S3.
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Comprehensive Genomic Analysis of ChRCCmRNA, miRNA, and DNA methylation (Table S5); many of these
correlates were shared with those previously observed for
ccRCC (Cancer Genome Atlas Research Network, 2013) and
included cell cycle genes, but not the ‘‘Warburg effect’’-like
patterns of aggressive ccRCC (Cancer Genome Atlas Research
Network, 2013).
Pathway and mtDNA Analysis
When viewed in the context of mitochondrial function, expres-
sion of nuclear-encoded genes in ChRCC, with compared to
normal kidney, suggested increased utilization of the Krebs cycle
and electron transport chain (ETC) for ATP generation (Figure 3A;
Figures S3A and S3B). In ChRCC, nearly all genes encoding
enzymes in the Krebs cycle showed increased expression
over normal, with the entry of pyruvate into the Krebs cycle via
acetyl coenzyme A likely through the pyruvate dehydrogenase
complex. Concordantly, all complexes of the ETC demonstrated
mRNA increases in at least one gene. These patterns could
reflect an increased level of mitochondrial biosynthesis, resulting
in greater numbers of mitochondria within each tumor cell; this
possibility is supported by both the increased expression of
mitochondrial biogenesis regulator PPARGC1A (p < 1 3 105,
t test using log-transformed data; Table S3) and increased mito-
chondrial genome copy numbers (four times more on average
in ChRCC versus normal kidney; Figure 3B; Figure S3C). These
findings interestingly parallel the eosinophilic histology observed
in some ChRCC, corresponding to the high uptake of eosin by
mitochondria. Eosinophilic ChRCC tumors share many features
with the benign variant oncocytoma, which is also characterized
by dense accumulations of mitochondria (Amin et al., 2008;
Tickoo et al., 2000). Furthermore, the gene expression land-
scape appeared very different from that of ccRCC, in which
expression of genes involved in mitochondrial functions is
strongly suppressed (Figure S3D) (Cancer Genome Atlas
Research Network, 2013). These findings suggest that various
bioenergetics strategies may support tumor growth and thatCancer Cell 26, 319–330, Snot all cancers necessarily seek to
minimize their reliance upon oxidative
phosphorylation (Cancer Genome Atlas
Research Network, 2013).
Given the indicated prevalent role of
mitochondria in ChRCC and the likelihoodof rapid mitochondrial genome replication (Figure 3B), we
sequenced mtDNA from 61 of our 66 ChRCC cases, using a
PCR-based amplification approach (Table S6). In all, we identi-
fied 142 somatic mutation events (i.e., not present in the normal)
at various levels of heteroplasmy (i.e., mixture with other vari-
ants), 75 of these residing within the commonly altered D-loop
noncoding region (Chatterjee et al., 2006). Thirty-five mutation
events (involving 27 cases) were present in over 50% of mtDNA
copies in the tumor (>50% heteroplasmy) (Figure 4A). Human
mtDNA encodes 13 proteins involved in respiration and oxidative
phosphorylation (Figure 3A), and we found 15 nonsilent muta-
tions in 12 ChRCC cases involving these genes (>50% hetero-
plasmy), all of which validated using alternative strategies,
including whole-genome sequencing (WGS)-based analysis
(Larman et al., 2012) (Table S6). On the basis of previous
functional studies in oncocytoma (Gasparre et al., 2008; Mayr
et al., 2008; Simonnet et al., 2003), and because many of our
variants represented frameshift substitutions, these mtDNA
mutations are thought, in general, to lead to inactivation, rather
than activation, of the associated protein.
ETC complex I genes were altered in 18% of cases (n = 11;
Figures 1B and 3A; Table S3); the most frequently altered gene
was MT-ND5, in six cases (all with >70% heteroplasmy), with
five of these being histologically classified as eosinophilic
ChRCC (p < 0.01, one-sided Fisher’s exact test) and three
showing no copy-number abnormalities (p < 0.002). MT-ND5 is
essential for the activity of complex I (Chomyn, 2001), which is
responsible for the transfer of electrons from NADH to ubiqui-
none. One ChRCC case had a single base insertion at position
12417 that changes the length of an 8-bp homopolymer tract
inMT-ND5, which has been observed previously in several other
cancer types (Larman et al., 2012); another case had an insertion
at 12384, at which position a mutation was found elsewhere
in oncocytoma and associated with loss of complex I activity
(Mayr et al., 2008). Two ChRCC cases each had single-base
deletions at position 13230 of MT-ND5, but no other mtDNAeptember 8, 2014 ª2014 Elsevier Inc. 323
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Figure 4. Integrative Analysis of mtDNA Mutations in ChRCC
(A) mtDNA somatic mutations (with >50% heteroplasmy) in 61 ChRCCs, by LR-PCR method. Red, variants that result in amino acid change.
(B) Gene expression difference (719 genes with p < 0.001 by t test, FDR < 0.05) between ChRCC cases harboring MT-ND5 mutations in most mtDNA copies
(>70% heteroplasmy) versus other ChRCCs.
(C) Expression of nuclear-encoded subunits of complexes I to V, or ‘‘OX-PHOS,’’ in ChRCCand ccRCC, with (>50%heteroplasmy) or without harboring complex I
(Cx I) mutations, relative to normal kidney.
See also Figure S4 and Table S6.
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mutated ChRCC cases to have a distinct gene transcrip-
tion signature (Figure 4B; Figures S4A and S4B; 719 genes
with p < 0.001 by t test, FDR < 0.05), which was shared by other
eosinophilic cases and not limited to genes in regions of recur-
rent copy-number abnormality (Figure S4C). Genes with high
expression in MT-ND5-mutated cases were enriched for those
associated with mitochondria (43 with Gene Ontology term
‘‘mitochondrion;’’ p < 5 3 106, one-sided Fisher’s exact test),
including several with roles in ETC (SDHB, NDUFS1, ATP5F1,
COX10, and COX11; Table S3). Notably, mutations in complex
I did not result in expression patterns associated with loss of
oxidative phosphorylation (Figure 4C), as might be assumed
(Larman et al., 2012), suggesting possible alternative roles for
complex I alteration in cancer-associated metabolic activity
(Figure S4D). The associations made here, involving mtDNA
mutations with mitochondrial abundance and differential gene
expression patterns (whichmay be unique to ChRCC and related
cancers), could perhaps suggest either a compensatory role for
loss of complex I function or selective pressures operating to
promote alternative pathways.
Whole-Genome Analysis
WGS for 50 of our 66 ChRCC cases was performed (603 and
303 coverage for paired tumor and normal, respectively). The
Meerkat algorithm (Yang et al., 2013) was applied to detect
genomic rearrangements, with an average of 16 found per
case (range 0–207; Figure S5A), but without involving recurrent324 Cancer Cell 26, 319–330, September 8, 2014 ª2014 Elsevier Incgene-gene fusions. By WGS analysis, a subset of ChRCC
manifested kataegis (Figure 5A; Figure S5B), a phenomenon
involving highly localized substitution mutations (C > T or C >
G). Consistent with observations in other cancers (Alexandrov
et al., 2013; Nik-Zainal et al., 2012), we found that regions of
kataegis in ChRCC were in the vicinity of genomic rearrange-
ments (Figure 5A; Figure S5B; average of 150 rearrangements
by pter/qter region). Three ChRCCWGS profiles showed partic-
ularly strong patterns involving chromosomal region 3p, 5p, 5q,
8q, 13q, or 15q (Figure 5B). A mutation signature consistent
with APOBEC cytidine deaminase activity (Alexandrov et al.,
2013; Roberts et al., 2013) was significantly enriched in
kataegis regions as well as in tightly spaced mutation clusters
forming kataegis events (Figures S5C–S5F and Table S7).
Although not detectable in ChRCC WES data (Alexandrov
et al., 2013), WGS mutation spectra of six ChRCC cases,
including the three with strong kataegis patterns, showed statis-
tically significant (albeit moderate) APOBEC-patterned muta-
genesis across the entire genome (Figure S5C). APOBEC3B
mRNA expression was also elevated in ChRCC compared with
normal kidney (Figure S5G).
We compared gene expression profiles between ChRCC
cases with and without a strong kataegis pattern (n = 3 and
n = 47, respectively) and identified 29 differentially expressed
genes (FDR < 0.05) including TERT (p < 1 3 1010, t test,
FDR < 1 3 106; Figure 5C). The TERT gene itself showed a
wide range of expression levels across ChRCC, from undetect-
able to hundreds of units by RNA sequencing. Focusing our.
AB C D
E
Figure 5. Kataegis and TERT in ChRCC
(A) Examples of a strong kataegis pattern in two ChRCC cases. ‘‘Rainfall’’ plots of mutations by WGS order events by genomic location. Vertical axis denotes
genomic distance of each mutation from the previous mutation.
(B) WGS profiles for 50 ChRCC cases, each scored by genomic region (chromosome pter/qter) for kataegis. The 3 ChRCC cases scoring particularly strong are
indicated at the bottom. Score for a given region represents a one-sided Fisher’s exact test, for enrichment of C > T or C > G mutations involving intermutation
distances below 10 kb (corrected for testing of multiple regions).
(C) A set of 29 differentially expressed genes (FDR < 0.05), including TERT, observed in ChRCC cases with strong kataegis versus other ChRCC.
(D) Copy variation and DNA breakpoint analysis identifying genomic rearrangements involving the promoter region of TERT for the 50 ChRCC cases (case
ordering the same for B, C, and D). The 6 cases harboring rearrangements involving TERT are indicated (pink triangles).
(E) TERT expression levels in the ChRCC cases with TERT promoter SV, in the ChRCC cases with TERT promoter mutation (SNV), and in the remaining cases,
as well as in normal kidney samples; p values by two-sided t test on log-transformed data. Box plots represent 5%, 25%, median, 75%, and 95%.
See also Figure S5 and Table S7.
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Comprehensive Genomic Analysis of ChRCCattention on TERT, we sequenced the promoter region for
recently identified mutations (C228T and C250T) (Huang et al.,
2013); three cases harbored C228T mutations but were associ-
ated with only marginal TERT expression levels (average expres-Casion 1 unit). WGS analysis of DNA copy within the TERT region
identified some copy-number variation, but not at levels that
would account for the extent of deregulated expression. How-
ever, multiple cases did show abrupt changes in copy number,ncer Cell 26, 319–330, September 8, 2014 ª2014 Elsevier Inc. 325
Table 2. SVs Associated with TERT Promoter Region by WGS Analysis
Case
Breakpoint A Breakpoint B
Event Type
TERT
Expressionb Confirmedcchr:pos oria Gene (Intron) chr:pos ori Gene
KL-8341 5:1116986 1 5:1296148 1 TERT PM tandem duplication 2,169.87 yes
KN-8435 5:272199 1 PDCD6 (I1) 5:1296716 1 TERT PM inversion 417.42 yes
KM-8438 5:1348783 1 5:1295372 1 TERT PM deletion 356.10 yes
KL-8346 5:1125430 1 5:1295604 1 TERT PM tandem duplication 67.50 yes
KL-8323 5:49560803 1 5:1299528 1 TERT PM tandem duplication 10.37 yes
KL-8323 5:49563017 1 5:1297603 1 TERT PM deletion-insertion 10.37 no
KM-8443 13:52688659 1 NEK5 (I4) 5:1305300 1 TERT PM interchromosomal translocation 9.13 yes
See also Figure S7.
aDenotes whether the upstream (+1) or downstream (1) sequence was fused relative to the given coordinates.
bAcross 66 ChRCC cases, 90th percentile of expression for TERT mRNA was 5.28 units by RNA sequencing.
cConfirmation using PCR across breakpoint junction, with subsequent sequencing of PCR product by PacBio platform. No PCR product was success-
fully obtained for one of the two breakpoints for KL-8323, likely due in part to the complexity of rearrangements in this case.
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Comprehensive Genomic Analysis of ChRCCat points that fell within the region 10 kb upstream of the TERT
transcription start site (Figure 5D). This observation suggested
the existence of structural breakpoints, leading us to reexamine
our Meerkat-generated results with greater scrutiny.
SubsequentWGS analysis identified genomic rearrangements
involving the TERT promoter region, leading to breakpoints
within the region in six out of 50 ChRCC cases (Figure 5D and
Table 2); these cases also had the highest levels of TERT ex-
pression (average > 500 units, p < 1 3 1020, t test; Table 2
and Figure 5E), even compared with cases with 228T mutation,
and three showed the strongest manifestation of kataegis (p =
0.001, one-sided Fisher’s exact). In five ChRCC cases, the
TERT-associated rearrangements were intrachromosomal (one
involving part of PDCD6), while the sixth case involved NEK5
on chromosome 13.When considering intratumor heterogeneity,
in most cases, these variants were estimated to reside in
nearly all of the cells (when counting the numbers of concordant
versus discordant read pairs), which would indicate that the
TERT-associated rearrangements represent early events and
therefore possible drivers. Of the seven rearrangements identi-
fied by WGS, we confirmed six (involving six cases) by PCR,
by designing primers that spanned both sides of the breakpoint
junction (Figure 6A; Table S8), allowing amplification of DNA
spanning the breakpoint region in the tumor sample (Figure 6B;
Figure S6); subsequent sequencing of the PCR product indepen-
dently confirmed the junction in each case (Figure 6C). Although
point mutations in the TERT promoter, leading to upregulation
of TERT itself, have been recently reported in cancers such as
melanoma (Heidenreich et al., 2014; Huang et al., 2013), our
results represent another phenomenon, of recurrent genomic
rearrangement breakpoints in the TERT promoter being asso-
ciated with elevated TERT expression in cancer. A precise
mechanism remains to be elucidated, though, as a result of
rearrangement, a number of cis-regulatory elements were found
to be placed in close proximity to the core promoter of TERT
(Figure S7).
DISCUSSION
With this comprehensive molecular survey of ChRCC, we have
made several important findings, in particular the observed326 Cancer Cell 26, 319–330, September 8, 2014 ª2014 Elsevier Increcurrent genomic structural rearrangements involving the
TERT promoter region and elevated TERT expression, and our
results raise intriguing questions regarding cancer, involving
the role of mtDNA alterations and the role of the cell of origin.
The above key findings were made possible only by our com-
prehensive approach, whereby, for example, we had no prior hy-
potheses regarding TERT at the outset of our study. Additionally,
mtDNAmutations in cancer, particularly those involvingMT-ND5
and complex I, have been hypothesized elsewhere to recapitu-
late the Warburg effect (Larman et al., 2012), though the corre-
sponding expression and histological patterns observed in our
datawere consistent with a complexmetabolic phenotype rather
than simple loss of oxidative phosphorylation. Taken together,
our key findings further illustrate the need to survey cancers
outside of exome boundaries, for example, by incorporating
WGS or mtDNA sequencing as part of an integrative, multiplat-
form analysis.
Through integration of molecular data from less common
cancers, we can learn more about more frequently encountered
diseases. Here, for example, our analysis of ChRCC led to addi-
tional insights regarding ccRCC. RCC represents a collection of
highly distinct tumors arising from different lineages within the
nephron, with distinct molecular and genetic features reflecting
independent processes of tumorigenesis (Linehan, 2012). Given
the complexity of function assigned to an organ such as the
kidney, different cancers arising from this organ may not neces-
sarily appear similar to each other (Alexandrov et al., 2013; Can-
cer Genome Atlas Network, 2012). Our multiplatform analyses
clearly confirm that ChRCC is a distinct disease entity from,
and shares little cell lineage or genomic characteristics with,
ccRCC, further reinforcing the notion that disease-specific
therapies are needed for rarer tumors such as ChRCC, rather
than simply adopting conventional therapeutic strategies used
for ccRCC. Given the clear genetic differences between ChRCC
and ccRCC, our results would suggest cell of origin as a key
factor in disease determination, observations that could inform
future efforts to fractionate the pool of susceptible cells for
ChRCC or ccRCC modeling or preventative interventions. In
addition, these data will serve as a resource for future explora-
tions of other tumors of kidney origin, such as papillary RCCs,
while being broadly relevant aswell to the study of other cancers,.
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Figure 6. Genomic SVs Involving TERT
Promoter
(A) Schematic representation of the PCR approach
used to validate TERT promoter SVs in the six
ChRCC cases and the DNA sequence surrounding
the breaking point in each case. For each SV, PCR
primers (P1/P2/P3/P4) were designed to span both
sides of the breakpoint junction, as illustrated.
(B) For case KN-8435 (as an example), DNA
spanning the SV breakpoint region could be
amplified in the tumor sample (but not in the paired
normal sample).
(C) For each of the six cases, amplified DNA
representing SV was confirmed by sequencing
(PacBio platform, which features long reads), with
sufficient reads and expected length of the PCR
product being observed (top, for KN-8435), and
with estimated breakpoint positions being close
to those of WGS results (bottom).
See also Figure S6 and Table S8.
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Comprehensive Genomic Analysis of ChRCCas metabolic, genomic structural alterations, and cellular factors
that influence the spectrum of genetic events contributing to
cancer development are further realized.
The gene expression patterns, increased mitochondrial
numbers, and histological patterns associated with ChRCC allCancer Cell 26, 319–330, Sindicate an increased importance of a
distinct mitochondrial respiration pro-
gram in this disease. Renal oncocytoma,
a benign renal tumor that, like ChRCC,
may also arise from the distal nephron,
shares several similarities with ChRCC
(particularly with its eosinophilic subtype),
including abundant, eosinophilic cyto-
plasm and densely packed mitochondria
(Amin et al., 2008; Tickoo et al., 2000).
Mitochondrial accumulation in renal
oncocytomas has been hypothesized
to be a compensatory mechanism for
inefficient oxidative phosphorylation (Si-
monnet et al., 2003), whereby loss of
complex I activity may result from somat-
ically acquired homoplasmic mutations in
mitochondrial complex I genes (Gasparre
et al., 2008; Mayr et al., 2008; Simonnet
et al., 2003). However, gene expression
in ChRCC would indicate that increased
oxidative phosphorylation is maintained
in complex I-altered tumors, suggesting
a metabolic shift supporting the growth
of this tumor, and counter to the
Warburg-like phenomenon observed in
high-grade, high-stage ccRCC and many
other cancers (Cancer Genome Atlas
Research Network, 2013), which would
appear consistent with previous observa-
tions, using metabolic imaging to demon-
strate uptake of radiolabeled acetate but
not glucose in ChRCC (Ho et al., 2012).In general, cancer cells derive much of their ATP through oxi-
dative phosphorylation (Ward and Thompson, 2012), and
cancer-associated reprogramming of mitochondria and of other
metabolic pathways, besides glycolysis and the Warburg effect,
has recently received much attention (Currie et al., 2013; Wardeptember 8, 2014 ª2014 Elsevier Inc. 327
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Comprehensive Genomic Analysis of ChRCCand Thompson, 2012). Further studies to dissect the precise role
of mtDNA alterations in cancer, and mitochondrial activities
promoting cancer growth, could shed light on how core meta-
bolic pathways may be altered in ChRCC and other malignant
diseases.
Our finding of recurrent DNA rearrangement breakpoints
within the TERT promoter region in over 10% of evaluated cases
represents a mechanism for increased TERT expression in
cancer different from point mutations observed in a wide variety
of cancers (Heidenreich et al., 2014; Huang et al., 2013), gene
amplification (Weir et al., 2007; Chudnovsky et al., 2005), and
germline polymorphisms (Rafnar et al., 2009). TERT is well
recognized as having roles in telomere maintenance and DNA
repair, in which deregulation of telomerase is a ubiquitous
feature of human cancers. The previously observed TERT pro-
moter mutations (C228T and C250T) create de novo E-twenty-
six/ternary complex factors binding sites, which have been
observed to increase transcriptional activity from the promoter
by 2- to 4-fold (Huang et al., 2013). Interestingly, the TERT
expression levels of the six cases with independently validated
TERT promoter rearrangements were much higher than those
cases with C228T promoter mutations, suggesting that these
rearrangements might have an even more potent effect on
upregulation of the gene. The precise mechanism of how these
rearrangements affect expression remains to be elucidated;
they could possibly involve rearranged cis-regulatory elements
or could allow the core TERT promoter to escape from the
native condensed chromatin environment (Zhao et al., 2009).
The observed association of TERT with kataegis is also intrigu-
ing. Elsewhere, rearrangement of DNA sequences upstream of
TERT has been reported in immortalized, nontumorigenic fibro-
blasts, leading to activated telomerase in cells surviving the
crisis stage of immortalization (Zhao et al., 2009), which involves
chromosomal instability and rearrangements due to loss of
telomere capping activity; in the setting of human cancer, this
would suggest that TERT-associated rearrangements would
be involved in many cases at an early stage in tumorigenesis.
Future applications of the information presented here will
include comparative analysis with other cancer types, for the
possible existence elsewhere of structural rearrangements
involving promoters for TERT or for other key drivers. As a
resource with a large set of whole-genome sequences, inte-
grated with a broad array of high-quality platform data sets,
other relationships between genomic structural alterations and
transcriptional components, including noncoding RNAs, remain
to be uncovered. As our data represent single biopsies, future
studies might focus on heterogeneity between biopsies from
the same tumor (Gerlinger et al., 2012); additionally, subclonal
analysis may shed light on early versus late somatic events in
ChRCC tumorigenesis. Our study also revealed that divergent
approaches for uncovering mtDNA mutations (long-range PCR
[LR-PCR] versus WGS [Larman et al., 2012]) are highly comple-
mentary to each other, allowing WGS data from other cancers
to be similarly mined for mtDNA mutations, with the additional
step of combining these data with those of other platforms, in
order to better understand the role of themitochondria in cancer.
Finally, the underlying data sets presented here represent part
of an interlocking toolset, which can be combined with those
of other cancers (Cancer Genome Atlas Research Network328 Cancer Cell 26, 319–330, September 8, 2014 ª2014 Elsevier Incet al., 2013), for further discovery of driver alterations, both within
and beyond the exome.
EXPERIMENTAL PROCEDURES
Patient and Sample Characteristics
With informed consent, biospecimens were collected from newly diagnosed
patients with ChRCC undergoing surgical resection and who had received
no prior treatment for their disease. Samples were obtained with approval
from institutional review boards at Brigham and Women’s Hospital, Memorial
Sloan-Kettering Cancer Center, the National Cancer Institute, and The Univer-
sity of Texas MD Anderson Cancer Center. Using a coisolation protocol, DNA
and RNAwere purified. Details of sample preparation are described in Supple-
mental Experimental Procedures.
Data Generation
In total, 66 ChRCC cases were assayed on at least one molecular profiling
platform (Table 1), which platforms included (1) RNA sequencing, (2) DNA
methylation arrays, (3) miRNA sequencing, (4) Affymetrix SNP arrays, (5)
WES, (6) WGS, and (7) mtDNA sequencing (using LR-PCR to amplify mtDNA).
As described above and in Supplemental Experimental Procedures, both
single-platform analyses and integrated cross-platform analyses were per-
formed. Sequence files are available from CGHub (https://cghub.ucsc.edu).
All other molecular, clinical, and pathological data are available through the
TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/).
WGS and WES Analysis
Massively parallel sequencing exome capture was performed using Nimble-
Gen (custom designed) VCRome 2.1 (42 MB) according the manufacturer’s
instructions. All exome sequencing and WGS was performed on the Illumina
HiSeq platforms. Basic alignment and initial sequence analysis were carried
out using the Mercury analysis pipeline (Reid et al., 2014).
mtDNA Sequencing Analysis
mtDNA was isolated from tissue samples using LR-PCR methods. Amplified
mtDNA PCR products were constructed into Illumina paired-end libraries,
and raw sequence data were preprocessed and aligned using the Mercury
pipeline.
RNA Sequencing Analysis
Both mRNA and miRNA libraries were separately generated from total RNA
and constructed using manufacturer protocols. Sequencing was done on
the Illumina HiSeq platform. Read mapping and downstream data analysis
were performed as described in Supplemental Experimental Procedures.
Array Data Analysis
DNA was hybridized to Affymetrix SNP 6.0 arrays and Illumina Infinium
HumanMethylation450 (HM450) BeadChip arrays, according to manufacturer
protocols.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.07.014.
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